Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023)

Ovid Therapeutics (OVID) has reported Other Operating Expenses for 8 consecutive years, with -$1000.0 the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Other Operating Expenses fell 100.48% year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2023 stood at -$1000.0 (down 100.13% YoY), and the FY2021 full-year result was -$45690.0, down 111.56% from the prior year.
• Other Operating Expenses fell to -$1000.0 in Q1 2023 per OVID's latest filing, from $836085.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $836085.0 in Q3 2022 and bottomed at -$438260.0 in Q4 2020.
• Historically, Other Operating Expenses has averaged $109971.6 across 5 years, with a median of $3280.0 in 2021.
• The sharpest annual moves came in 2019 and 2022: Other Operating Expenses surged 58195.11% in 2019, then tumbled 11188.32% in 2022.
• Over 5 years, Other Operating Expenses stood at $298720.0 in 2019, then sank by 246.71% to -$438260.0 in 2020, then surged by 100.89% to $3903.0 in 2021, then surged by 21321.6% to $836085.0 in 2022, then sank by 100.12% to -$1000.0 in 2023.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$1000.0, $836085.0, and -$284127.0 for Q1 2023, Q3 2022, and Q2 2022 respectively.